Stock comparison
Mettler-Toledo International
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 66C | MTD |
| Benjamin Graham | 65B | 84A | RPRX |
| Philip Fisher | 63C | 65C | RPRX |
| Peter Lynch | 66B | 60C | MTD |
| Joel Greenblatt | 68B | 40D | MTD |
| Charlie Munger | 74B | 68D | MTD |
| Terry Smith | 70B | 58D | MTD |
Side-by-side metrics
| Metric | MTD | RPRX |
|---|---|---|
| Market cap | $22.29B | $23.44B |
| P/E (TTM) | 25.3x | 27.6x |
| EV/EBIT | 21.6x | 19.9x |
| ROIC (TTM) | 36.09% | 8.43% |
| Gross margin | 57.79% | 99.95% |
| Net margin | 21.4% | 33.91% |
| Revenue CAGR 5y | 2.01% | 0.96% |
| EPS CAGR 5y | 6.12% | 11.83% |
| Debt / Equity | - | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 1.3x+102%
- ROIC (TTM)36.09%vs 8.43%+77%
- Revenue CAGR 5y2.01%vs 0.96%+53%
- P/E (TTM)25.3xvs 27.6x+8%
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- EPS CAGR 5y11.83%vs 6.12%+48%
- Gross margin99.95%vs 57.79%+42%
- Net margin33.91%vs 21.4%+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.